Litigation Details for Noven Pharmaceuticals, Inc. v. Mylan Technologies Inc. (D. Del. 2017)

« Back to Dashboard

Noven Pharmaceuticals, Inc. v. Mylan Technologies Inc. (D. Del. 2017)

Docket		Date Filed	2017-12-08
Court	District Court, D. Delaware	Date Terminated	2018-08-31
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	9,724,310; 9,730,900; 9,833,419
Link to Docket	External link to docket

Details for Noven Pharmaceuticals, Inc. v. Mylan Technologies Inc. (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-12-08				External link to document
2017-12-07	1		infringement of U.S. Patent Nos. 9,730,900 (“the ’900 patent”) and 9,724,310 (“the ’310 patent”) (collectively…of the ’900 patent. COUNT III – INFRINGEMENT OF U.S. PATENT NO. 9,724,310 154.… INFRINGEMENT OF U.S. PATENT NO. 9,724,310 168. Noven repeats and realleges…collectively, “patents-in-suit”) arising under the United States Patent Laws, Title 35, United States Code § …includes acts of patent infringement in the State of Delaware, including acts of patent infringement with	External link to document
2017-12-07	26		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,833,419 B2; . (Kraftschik, …2017 31 August 2018 1:17-cv-01777 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Noven Pharmaceuticals v. Mylan Technologies: Litigation Summary and Patent Analysis, 1:17-cv-01777

Last updated: August 28, 2026

Noven Pharmaceuticals sued Mylan Technologies in the U.S. District Court for the District of Delaware over Mylan's abbreviated new drug application for a generic version of Minivelle, Noven's transdermal estradiol system. The dispute involved U.S. Patent Nos. 8,231,935 and 8,486,058, which claimed low-dose estradiol transdermal systems and adhesive compositions. The case was part of Noven's broader patent enforcement campaign against generic Minivelle applicants.

The litigation risk ultimately turned on patent validity rather than infringement. The asserted claims were found unpatentable as obvious, consistent with earlier Federal Circuit and Patent Trial and Appeal Board decisions involving related Noven estrogen-patch patents. The outcome materially reduced the value of the listed Minivelle patents as barriers to generic entry.

What drug and product did Noven Pharmaceuticals sue Mylan over?

The case concerned Minivelle, an estradiol transdermal patch used for treatment of moderate-to-severe vasomotor symptoms associated with menopause and for prevention of postmenopausal osteoporosis.

Item	Detail
Brand	Minivelle
Active ingredient	Estradiol
Dosage form	Transdermal patch
Sponsor and patent owner	Noven Pharmaceuticals, Inc.
Parent company	Hisamitsu Pharmaceutical Co., Inc.
Generic pathway	ANDA under the Hatch-Waxman Act
Defendant	Mylan Technologies Inc.
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:17-cv-01777
Technology	Estradiol delivery through a transdermal adhesive system

Mylan Technologies manufactures transdermal systems and was the relevant Mylan entity for a patch product. Noven alleged that Mylan's proposed generic product would infringe patents listed for Minivelle in the FDA's Orange Book.

What patents did Noven assert against Mylan?

Noven asserted U.S. Patent Nos. 8,231,935 and 8,486,058.

Patent	General subject matter	Filing and priority profile	Nominal patent term
U.S. 8,231,935	Estradiol-containing transdermal delivery system	Continuation-family patent claiming priority to earlier Noven patch applications	Approximately 2027, subject to patent-term adjustment
U.S. 8,486,058	Transdermal drug delivery system and adhesive formulation	Related continuation-family patent	Approximately 2027, subject to patent-term adjustment

The patents addressed more than the presence of estradiol alone. Their claims focused on the composition and performance of the patch, including adhesive characteristics, drug delivery, and the use of a transdermal system capable of delivering a low dose of estradiol.

The patents belonged to the same broader family that Noven had used to protect its transdermal estrogen portfolio. Earlier members of that family, including U.S. Patent Nos. 6,071,531 and 6,746,689, had also been challenged in patent litigation and inter partes review proceedings.

What was the procedural history of Noven v. Mylan, 1:17-cv-01777?

Noven filed the action after receiving a Paragraph IV certification from Mylan concerning the Minivelle patents. The certification asserted that the patents were invalid, unenforceable, or would not be infringed by Mylan's ANDA product.

Hatch-Waxman timeline

Event	Significance
Mylan filed an ANDA	Sought FDA approval for a generic estradiol transdermal system
Mylan served a Paragraph IV notice	Triggered Noven's right to sue for patent infringement
Noven filed in Delaware	Initiated the 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii)
Claim construction and validity proceedings followed	The dispute focused heavily on obviousness
District court judgment	The asserted claims were held invalid as obvious
Federal Circuit review of related Noven patent rulings	Confirmed the vulnerability of Noven's related patch claims

The 30-month stay did not create a permanent market barrier. It only delayed final FDA approval while the litigation proceeded, subject to the court's rulings and any settlement or appellate outcome.

What was the outcome of the case?

The central legal result was that the asserted Minivelle patent claims could not reliably block generic competition because they were invalid for obviousness.

The court's analysis was influenced by the existing record involving Noven's earlier estrogen-patch patents. The prior art disclosed transdermal estradiol systems, drug-in-adhesive patches, silicone and acrylic adhesive technologies, and approaches for controlling estradiol delivery. The dispute therefore concerned whether the claimed combination represented a nonobvious advance or an expected optimization of known patch technology.

The invalidity theory relied on the ordinary skill of a transdermal drug-delivery formulator and the predictability of selecting known adhesives and adjusting drug loading, patch area, and delivery characteristics. The asserted claims did not receive the benefit of strong objective indicia sufficient to overcome the obviousness showing.

The Federal Circuit's decisions involving related Noven patents were important because they rejected Noven's attempts to distinguish its estrogen-patch claims from the prior art. Those decisions limited the practical force of the remaining patent family in later district-court litigation.

Why did obviousness control the litigation?

What prior art affected the Noven patent estate?

The relevant technical background included:

• Transdermal estradiol patches;
• Drug-in-adhesive delivery systems;
• Silicone adhesive matrices;
• Acrylic adhesive systems;
• Low-dose hormone replacement products;
• Known methods for controlling estradiol flux and patch adhesion;
• Prior Noven and third-party disclosures involving estrogen delivery.

The court evaluated whether the claimed patch architecture reflected routine formulation work. A patent can cover a specific composition even when its individual components are known, but the combination must provide more than predictable results from ordinary optimization.

The court's reasoning treated the selection and adjustment of patch components as technically predictable. That weakened Noven's argument that the claims represented a nonobvious formulation breakthrough.

How did the earlier Noven patent decisions affect this case?

Noven previously litigated related patents against Mylan and other generic companies. In those proceedings, the Federal Circuit affirmed decisions that invalidated or sustained the invalidation of claims directed to Noven's transdermal estrogen technology.

Those rulings created several constraints:

1. They narrowed the remaining enforceable scope of the patent family.
2. They reduced Noven's ability to distinguish later continuation claims from earlier invalidated claims.
3. They supplied adverse factual findings concerning the prior art and the predictability of transdermal estradiol formulation.
4. They increased the probability that later Minivelle claims would face the same obviousness problem.

The practical lesson was that continuation patents did not automatically provide a second, independent exclusivity layer when their claims relied on the same technical disclosure and similar prior-art combinations.

What was the Orange Book status of Minivelle?

Minivelle's relevant patents were listed in the FDA Orange Book for the approved estradiol transdermal system. The listed patents supported Noven's Hatch-Waxman litigation against ANDA applicants.

Orange Book listing does not establish patent validity. It gives the brand sponsor a mechanism to assert the patent after a Paragraph IV certification and triggers the statutory approval stay. The listed patent can still be invalidated in district court or in an inter partes review.

What exclusivity did Minivelle have?

Minivelle's market protection involved both regulatory and patent exclusivity.

Protection	Approximate effect
New drug approval	Established FDA approval for the branded product
Three-year exclusivity	Potentially protected certain approved conditions of use based on required clinical investigations
Patent listing	Enabled Paragraph IV litigation and the 30-month stay
Patent term	Provided nominal protection into the late 2020s, subject to validity and term adjustments

The regulatory exclusivity period was not the principal long-term barrier in the Mylan case. The commercial dispute centered on the Orange Book patents and whether they could delay generic approval beyond the Hatch-Waxman litigation period.

When did Minivelle lose exclusivity?

Minivelle's effective exclusivity was weakened when the asserted patents were held invalid. A patent's nominal expiration date is commercially irrelevant if the claims cannot withstand an invalidity challenge.

The relevant patents had terms extending approximately into 2027, subject to patent-term adjustment and the precise patent-family calculations. The earlier members of the family had earlier expiration dates. Because Noven's principal claims were vulnerable to obviousness attacks, the effective loss of exclusivity could occur before nominal patent expiration through a final invalidity judgment.

Generic entry depended on FDA approval, the final disposition of the litigation, any settlement terms, and the status of other Orange Book-listed patents. A final judgment of invalidity removes the patent-based obstacle, but it does not itself constitute FDA approval.

Did Mylan file a Paragraph IV challenge?

Yes. The action was a Hatch-Waxman Paragraph IV case. Mylan's ANDA certification placed Noven on notice that Mylan contended the Minivelle patents were invalid, unenforceable, or not infringed.

A Paragraph IV certification creates litigation exposure for the generic applicant but also gives it a route to challenge weak patents before commercial launch. The case illustrates the value of Paragraph IV litigation where the brand's patent estate depends on continuation claims that closely track previously challenged technology.

Was there patent infringement liability?

The case did not produce a durable infringement-based barrier because the asserted claims were invalid. In Hatch-Waxman litigation, courts often address infringement and validity in the same action. Even where an ANDA product is found to fall within the claim language, the brand cannot obtain meaningful injunctive relief on an invalid patent.

The commercial result therefore favored the generic applicant. The invalidity ruling eliminated the practical basis for using the asserted patents to prevent FDA approval or market entry.

What litigation affected Noven's broader estrogen-patch patent estate?

Noven's Minivelle portfolio was involved in multiple related proceedings involving generic manufacturers and inter partes review petitioners.

Proceeding type	Commercial effect
District-court Hatch-Waxman actions	Tested infringement and validity after ANDA Paragraph IV certifications
Inter partes review	Allowed generic or other challengers to attack patent claims before the PTAB
Federal Circuit appeals	Determined the final enforceability of challenged claims
Related continuation litigation	Tested whether later claims could avoid earlier adverse findings

The earlier IPR and Federal Circuit proceedings were particularly damaging to Noven's portfolio because they addressed core technical concepts rather than a narrow peripheral claim. Once those concepts were found obvious, later patents with similar disclosure faced a higher invalidity risk.

How strong was the Noven Minivelle patent estate?

The estate was technically relevant but legally fragile.

Strengths

• Covered a commercially important transdermal estradiol product.
• Included multiple continuation-family patents.
• Claimed specific adhesive and delivery-system configurations.
• Supported Hatch-Waxman litigation and approval stays.
• Created settlement leverage before final judgment.

Weaknesses

• The underlying technology used known transdermal delivery components.
• Earlier related claims had already faced successful validity challenges.
• The asserted claims depended on combinations that the court viewed as predictable.
• Continuation-family overlap made claim differentiation difficult.
• The patents did not provide biologic-style manufacturing complexity or formulation secrecy.

The estate had litigation value but limited durability after adverse obviousness rulings.

What generic entry risks existed for Minivelle?

The primary risk was rapid generic substitution after the patent barrier fell.

Generic substitution risk

Estradiol patches are comparatively amenable to generic competition because the product is a small-molecule dosage form, not a biologic. FDA approval depends on pharmaceutical equivalence, bioequivalence, manufacturing quality, and labeling requirements rather than biosimilar interchangeability.

Pricing risk

A generic transdermal estradiol product can pressure:

• Gross sales of Minivelle;
• Net price and rebate levels;
• Formulary positioning;
• Prescriber retention;
• Pharmacy substitution rates;
• Revenue from related estrogen products.

The magnitude of revenue loss depends on the number of approved generic applicants, launch timing, authorized generic strategy, payer coverage, and whether the generic product matches the full range of Minivelle strengths.

Biosimilar risk

Biosimilar risk was not relevant to this case. Minivelle contains estradiol, a small-molecule active ingredient, and generic competition proceeds through the ANDA pathway rather than the Public Health Service Act biosimilar pathway.

Did Noven have formulation and manufacturing barriers beyond the patents?

The patents addressed formulation and delivery-system characteristics, but those claims did not create an insurmountable manufacturing barrier.

A generic manufacturer still must develop:

• A reproducible adhesive matrix;
• Controlled estradiol loading;
• Uniform patch content;
• Stable release performance;
• Appropriate pouch and backing materials;
• Manufacturing controls for adhesion, crystallization, and dose uniformity.

Those development requirements can delay a generic program, but they are not equivalent to a durable patent monopoly. Once the technical specifications are known and the patents are invalidated, the barriers become development and regulatory execution issues.

What licensing deals or settlements affected the case?

Publicly available case materials do not establish a commercially material license that changed the final legal analysis in Noven Pharmaceuticals v. Mylan Technologies, 1:17-cv-01777. The operative issue was the validity of the asserted patents, not a publicly disclosed technology license.

Hatch-Waxman cases can end through a settlement that grants a generic an agreed launch date. Such settlements may preserve value for the brand even when the patents face validity risk. A settlement date, however, should not be treated as proof that the patents were valid or enforceable.

How does Noven's estate compare with other transdermal estrogen products?

Product category	Patent and regulatory profile	Generic risk
Minivelle	Estradiol patch with challenged formulation and delivery patents	High after invalidity rulings
Vivelle-Dot and related estradiol patches	Older transdermal estrogen technology with multiple generic products	Established generic competition
Climara	Estradiol patch with earlier brand exclusivity history	Generic competition
Estrogen gels and sprays	Different delivery technologies and formulation claims	Product-specific
Combination hormone patches	May have additional progestin and formulation barriers	Depends on active ingredients and claims

Minivelle's differentiation depended on low-dose delivery and patch design. Those characteristics supported branding but did not eliminate substitution once generic products obtained FDA approval.

Key Takeaways

• Noven sued Mylan over an ANDA for generic Minivelle, an estradiol transdermal patch.
• The asserted patents were U.S. Patent Nos. 8,231,935 and 8,486,058.
• The case was a Paragraph IV Hatch-Waxman action in the District of Delaware.
• Obviousness, not infringement, determined the commercial outcome.
• Related Noven estrogen-patch patents had already suffered adverse validity rulings.
• The patents had nominal terms extending into approximately 2027, but invalidity reduced their effective exclusivity.
• Minivelle faced generic, not biosimilar, competition.
• Formulation and manufacturing complexity created development costs but did not replace patent protection.
• The case weakened Noven's ability to rely on continuation patents to preserve exclusivity for the same underlying patch technology.

FAQs About Noven Pharmaceuticals v. Mylan Technologies

What was the case number for Noven Pharmaceuticals v. Mylan Technologies?

The case was filed in the District of Delaware as Civil Action No. 1:17-cv-01777.

What was Minivelle's active ingredient?

Minivelle contained estradiol and was supplied as a transdermal delivery system.

Which patent doctrine defeated Noven's claims?

The principal doctrine was obviousness under 35 U.S.C. § 103. The court considered whether the claimed transdermal systems were predictable combinations or optimizations of known technology.

Was Minivelle protected by a biologic patent estate?

No. Minivelle was a small-molecule estradiol product. Its generic pathway was an ANDA, and biosimilar rules did not apply.

What was the investment significance of the ruling?

The ruling reduced the reliability of Noven's late-life patent protection for Minivelle and increased the probability of generic price and volume pressure once regulatory approval and other procedural barriers were resolved.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

2. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

3. U.S. Patent and Trademark Office. (2024). Patent Center and Patent Examination Data System. USPTO.

4. Noven Pharmaceuticals, Inc. v. Mylan Technologies Inc., No. 1:17-cv-01777, U.S. District Court for the District of Delaware.

5. Noven Pharmaceuticals, Inc. v. Mylan Technologies, Inc., 853 F.3d 1289 (Fed. Cir. 2017).

6. Noven Pharmaceuticals, Inc. v. Mylan Technologies, Inc., related Federal Circuit and Patent Trial and Appeal Board proceedings concerning Noven's transdermal estradiol patent family.

7. Hatch-Waxman Amendments, 21 U.S.C. § 355(j).

8. 35 U.S.C. § 103.